DOH does not expect Omicron XE to dodge efficacy of vaccines
MANILA, Philippines — The Department of Health (DOH) does not expect the Omicron XE to dodge the efficacy of COVID-19 vaccines, a member of its Technical Advisory Group said Tuesday.
According to Dr. Edsel Salvana, Omicron XE is a recombinant of Omicron sub-lineages BA.1 and BA.2.
“Most of our vaccines really target BA.1 and BA.2 na medyo may (with) breakthrough infection,” Salvana said in a media forum.
“There’s always a possibility that it can come in but we don’t expect it to be more severe and we don’t expect it to dodge vaccines any worse than BA.1 or BA.2,” he further noted.
The World Health Organization (WHO) estimated that Omicron XE is 10-percent more infectious than the BA.2.
Recently, Thailand recorded its first case of the Omicron XE, a variant of SARS-CoV-2, the virus that causes COVID-19.
Following the reported case, the DOH assured the public that it is monitoring the situation and is in coordination with the WHO.
JPV
For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.
The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.
